Successful treatment of severe refractory aplastic anemia with 3-beta etiocholanolone and nandrolone decanoate.
A patient with aplastic anemia, who had been unresponsive to androgens, antithymocyte globulin, high-dose methylprednisolone, and cyclosporine, responded to treatment with 3-beta-etiocholanolone, nandrolone decanoate, and prednisolone acetate. Six months following initiation of therapy, she became red cell and platelet transfusion independent with neutrophils persistently over 1,000/microliters. A sustained partial remission has persisted for over 2 years. This observation suggests that a combined hematostimulatory approach may be of benefit, even in patients with long-standing refractory aplasia.
Seewald
T R
TR
Department of Medicine, Montefiore Hospital, University of Pittsburgh School of Medicine, PA 15213.
Zeigler
Z R
ZR
Gardner
F H
FH
D000741:Anemia, Aplastic / Q000097:blood / Q000188:drug therapy*; D001772:Blood Cell Count; D004351:Drug Resistance; D004359:Drug Therapy, Combination; D005043:Etiocholanolone / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008875:Middle Aged; D009277:Nandrolone / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000077603:Nandrolone Decanoate; D011239:Prednisolone / Q000031:analogs & derivatives / Q000627:therapeutic use
D009277:Nandrolone; C009935:prednisolone acetate; D005043:Etiocholanolone; D011239:Prednisolone; D000077603:Nandrolone Decanoate